Please ensure Javascript is enabled for purposes of website accessibility

Why Humanigen Stock Vaulted Higher Today

By Keith Speights - May 5, 2021 at 2:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Detailed results from a late-stage study of the company's lead candidate were published online.

What happened

Shares of Humanigen (HGEN -4.22%) were vaulting 10.8% higher as of 2:47 p.m. EDT on Wednesday. The gain came after the company announced the publishing of results on the online preprint site medRxiv from a phase 3 study evaluating lenzilumab in treating hospitalized COVID-19 patients.

So what

The late-stage study found that lenzilumab significantly improved survival without ventilation for hospitalized patients with COVID-19 compared to standard treatments of Gilead Sciences' remdesivir and/or corticosteroids by themselves. Patients with especially high inflammation levels and those under the age of 85 experienced the greatest benefit from receiving Humanigen's experimental therapy.  

Gloved hand in between fallen dominoes spelling "COVID-19" and standing blank dominoes

Image source: Getty Images.

Humanigen reported top-line results in late March from its phase 3 study of lenzilumab in treating hospitalized COVID-19 patients. The company stated at that time that it planned to submit the results for potential publication in a peer-reviewed journal. The online medRxiv site offers a way for researchers to share data before it's reviewed by peers. The additional details provided in the online preprint gave investors more confidence about the prospects for lenzilumab in treating COVID-19.

Now what

In March, Humanigen CEO Cameron Durrant said that the company planned to submit an application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for lenzilumab in treating COVID-19. Winning EUA for the experimental therapy would likely provide yet another major catalyst for the biotech stock.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Humanigen, Inc. Stock Quote
Humanigen, Inc.
$0.38 (-4.22%) $0.02
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.60 (0.83%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.